LOGIN  |  REGISTER
Amneal Pharmaceuticals
Terns Pharmaceuticals

The Oncology Institute to Participate at Upcoming Investor Conferences

May 31, 2023 | Last Trade: US$3.73 0.06 1.63

CERRITOS, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that senior management will participate at the following investor conferences:

2023 Jefferies Healthcare Conference
Date: June 9th, 2023
Fireside Chat: 11:00am Eastern Time
TOI Participant: Daniel Virnich, M.D., MBA, President
Location: New York City, NY

UBS Healthcare Services Conference
Date: June 26th – 28th, 2023
TOI Participant: Brad Hively, Chief Executive Officer
Location: Chatham, MA

Interested investors and other parties may listen to simultaneous webcasts of the presentations by logging onto the Investor Relations section of the Company’s website at https://investors.theoncologyinstitute.com/. The online replay will be available for a limited time shortly following the call.

About The Oncology Institute, Inc.

Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With 100+ employed clinicians and more than 700 teammates in over 60 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.

Contacts

Media

The Oncology Institute, Inc.
Daniel Virnich, MD
This email address is being protected from spambots. You need JavaScript enabled to view it.
(562) 735-3226 x 81125

Investors

Solebury Strategic Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.

Viking Therapeutics

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page